Topics
Glioblastoma | Treatment | Chemotherapy | Temozolomide | MGMT promoter methylation status
Home > Publications > Topics > Glioblastoma > Treatment > Chemotherapy > Temozolomide > MGMT promoter methylation status
*Hegi ME, Oppong FB, Perry JR, Wick W, Henriksson R, Laperriere
NJ, Gorlia T, Malmström A, Weller M; NCBTSG; NOA; CCTG;
EORTC-BTG.
No benefit from TMZ
treatment in GB with truly unmethylated MGMT promoter: Reanalysis
of the CE.6 and the pooled Nordic/NOA-08 trials in elderly GB
patients.
Neuro
Oncol. 2024 Jun 24:noae108. doi:
10.1093/neuonc/noae108. PMID:
38912869. Observational study. ˍ
*Wee CW, Lee JH, Lee HI, Kim J, Chang JH, Kang SG, Kim EH, Moon
JH, Cho J, Park CK, Kim CY, Hwang K, Yoon HI, Kim IA.
To
Use or Not to Use: Temozolomide in
Elderly Patients with IDH Wild-type
MGMT Promoter Unmethylated Glioblastoma
Treated with Radiotherapy.
Cancer
Res Treat. 2024 Nov 11. doi:
10.4143/crt.2024.945. PMID:
39529389. Observational study. ˍ